| Literature DB >> 27760336 |
Tara M Weitz1, Terrence Town2.
Abstract
In a recent issue of Nature, Sevigny et al. (2016) report findings from a phase 1b clinical trial of aducanumab (a monoclonal antibody targeting misfolded amyloid-β peptides), revitalizing the "amyloid cascade hypothesis" and bringing mononuclear phagocytes center stage in the treatment of Alzheimer's disease.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27760336 DOI： 10.1016/j.immuni.2016.10.006
Source DB: PubMed Journal: Immunity ISSN： 1074-7613 Impact factor: 31.745